（股份代號：2279） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 Yonghe Medical Group Co., Ltd. 雍禾醫療集團有限公司 （於開曼群島註冊成立的有限公司） 雍禾醫療集團有限公司 於本公告日期，本公司執行董事為張玉先生、張輝先生及韓志梅女士；本公司非 執行董事為耿嘉琦先生；以及本公司獨立非執行董事為梁繼紅女士、陳炳鈞先生 及李小培先生。 董事長 董事會會議召開日期 雍禾醫療集團有限公司（「本公司」及其附屬公司「本集團」）董事會（「董事會」）茲 通告謹定於2026年3月31日（星期二）舉行董事會會議，以考慮及通過本集團截至 2025年12月31日止的年度全年業績，及派發建議之末期股息（如有），以及處理其 他事項。 香港，2026年3月19日 承董事會命 張玉 ...

新消费导读 在雍禾女性战略发布会现场，我看到的是医美的一次结构变化。 这是新消费智库第 2 7 7 0 期文章 先给结论 ， 很多人还在把植发理解为一件 " 治脱发 " 的事。 作为一名观察者，我昨天在雍禾的发布会现场 ， 足足 待够 了 两 个 小 时， 我学习到 一件事： 这个行业已经变了。 不是我所以前所认知的这 样一个行业了。 叙 事 结 构 ， 发 生 了 根 本 性 的 变 化 ， 植 发 行 业 从 一 个 过 去 看 起 来 很 重 的 行 业，一种医疗行为， 变成一种新的审美 新 消 费 。 而 更 重 要 的 是 ： 雍 禾在告诉我， 毛发，正在成为 一种 " 变美 " 的新入口。 作者 ：龙猫君 来源：新消费智库 这不是一家公司的升级 ， 这是一个行业在换逻辑。 发布会现场，我看到的不是医疗，是 " 美学 " 与 "设计" 说实话，我原本是带着 " 行业观察 " 的心态去这场发布会的。但现场给我的第一感受， 并不只是简单的 医疗。 而是： 设计。 你会发现，这场发布会几乎没有在强调 " 手术成功率 " 这种传统医疗话术。取而代之的是一整套新的语言体系： 四庭七眼 、 花瓣型发际线 、 中 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 Yonghe Medical Group Co., Ltd. （股份代號：2279） 內幕消息 正面盈利預告 本公告乃雍禾醫療集團有限公司（「本公司」，連同其子公司合稱「本集團」）遵照香 港聯合交易所有限公司證券上市規則（「上市規則」）第13.09(2)條及香港法例第571 章證券及期貨條例第XIVA部項下的內幕消息條文（定義見上市規則）而作出。 本公司董事會（「董事會」）謹此知會本公司股東（「股東」）及本公司潛在投資者， 根據對本集團截至2025年12月31日止年度（「該年度」）之未經審核合併管理賬目 以及董事會現時可得數據的初步審閱，本集團估計於該年度的淨利潤不少於人民 幣70.0百萬元，而截至2024年12月31日止年度的虧損為人民幣226.6百萬元。 根據目前可得資料，董事會認為本集團於該年度實現扭虧為盈，主要得益於以下 措施的持續推進與深化，該等措施不僅為本年度實現盈利奠定了堅實基礎，也為 本 ...

致：香港交易及結算所有限公司 公司名稱: 雍禾醫療集團有限公司 呈交日期: 2026年3月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02279 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 20,000,000,000 | USD | | 0.0000025 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 20,000,000,000 | USD | | 0.0000025 | USD | | 50,000 | 本月底法定/註冊股本總額： USD 50,000 FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 第 1 頁 共 10 頁 v 1.2.0 公司名稱: 雍禾醫療集團有限公司 呈交日期: 2026年2月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02279 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 20,000,000,000 | USD | | 0.0000025 USD | | 50,000 | | 增加 / 減少 (-) | | | | | | USD | | | | 本月底結存 | | | 20,000,000,000 | USD | | 0.0000025 USD | | 50,000 | 本月底 ...

Core Insights - The report provides an analysis of the hair medical industry in China, highlighting key players, market share, and competitive dynamics. Group 1: Industry Overview - The main listed companies in the hair medical industry include Yonghe Medical, Xianju Pharmaceutical, ST Meigu, Yisheng Pharmaceutical, Zhendong Pharmaceutical, International Medical, Kanghui Pharmaceutical, Kangyuan Pharmaceutical, Kang Enbei, and Furuida [1]. - The competitive landscape shows that companies with registered capital exceeding 1.5 billion yuan are in the leading position, while those with capital between 500 million to 1.5 billion yuan are in the first tier, and companies with less than 500 million yuan are in the second tier [1]. Group 2: Regional Distribution - Representative enterprises in the hair medical industry are mainly distributed across provinces such as Shaanxi, Zhejiang, Jilin, Liaoning, Shandong, and Jiangsu, with a notable concentration in Shaanxi and Zhejiang [4]. Group 3: Market Dynamics - As of November 21, 2025, leading hair transplant chains like Yonghe Hair Transplant, Dama Micro-needle (Kefa Source), and Bilian Sheng have over 30 stores each [7]. - The market for Minoxidil, a common hair growth medication, is highly concentrated, with the top three brands holding over 97% market share in online pharmacies as of 2024 [10][14]. Group 4: Competitive Analysis - The hair transplant sector has many institutions with low concentration, leading to intense competition, while the market for Minoxidil is dominated by a few key players [12][16]. - The threat of new entrants is moderate due to certain industry barriers, while substitutes like wigs and hair tattoos pose a threat due to their lower cost and quicker application [16].

Group 1 - The core point of the article is that Yonghe Medical (02279.HK) experienced a significant intraday increase, rising over 18% at one point and closing with a gain of 13.79% at HKD 1.98 [1] - The trading volume for Yonghe Medical reached HKD 2.2049 million [1]

Core Viewpoint - Yonghe Medical (02279) experienced a significant stock price increase, reaching a high of 2.1 HKD, marking the highest level since October of the previous year, driven by positive developments in its business operations and international collaborations [1] Company Summary - Yonghe Medical reported a revenue of 862 million RMB for the first half of the year, with a net profit attributable to shareholders of 27.91 million RMB, indicating a turnaround from previous losses [1] - As of June 30, 2025, the company operates 63 hair transplant medical institutions across 61 cities in China, making it the largest and most widely covered chain in the hair medical sector [1] - The total number of consumers served by the company reached 64,845 in the six months ending June 30, 2025, reflecting strong demand for its services [1] Industry Summary - The visit from the French Embassy's medical team to Yonghe Medical's Beijing headquarters highlights the company's competitive advantages in hair transplant and hair care services, as well as its strategic location near the embassy district [1] - The company expressed a willingness to enhance cooperation with the embassy, indicating potential for future partnerships and growth in the international market [1] - CICC previously noted that optimized store layout and refined marketing strategies have contributed to improved operational efficiency and profitability for the company [1]

Core Viewpoint - Yonghe Medical (02279) has seen a significant stock price increase, reaching a high of 2.1 HKD, marking the highest level since October of the previous year, driven by positive developments in its business and international collaborations [1] Group 1: Company Developments - Yonghe Medical's stock price rose over 18% during trading, with a current increase of 13.79% to 1.98 HKD and a trading volume of 2.2049 million HKD [1] - A delegation from the French Embassy in China visited Yonghe Medical's Beijing headquarters to experience AI scalp detection and hair care services, highlighting the company's strengths in hair transplant and care [1] - The company expressed a willingness to provide hair medical services to embassy staff, indicating potential for future collaboration [1] Group 2: Financial Performance - For the first half of the year, Yonghe Medical reported revenue of 862 million RMB and a net profit attributable to shareholders of 27.913 million RMB, marking a turnaround from previous losses [1] - As of June 30, 2025, the company operates 63 hair transplant medical institutions across 61 cities in China, making it the largest and most widely covered chain in the hair medical sector [1] - The total number of consumers served by the company reached 64,845 in the first half of the year, reflecting its operational scale and market presence [1] - CICC previously indicated that optimized store layout and refined marketing strategies have contributed to improved operational efficiency and profitability [1]

Core Viewpoint - Yonghe Medical (2279.HK) experienced significant trading activity today, with its stock price surging over 20% to reach HKD 2.1, marking a new high since October 2025 [1] Group 1 - The stock price increase indicates strong market interest and potential investor confidence in Yonghe Medical [1] - The rise in stock price reflects a positive trend for the company, achieving a three-month high [1]